SCHEDULE 13G/A: BlackRock Discloses 5.5% Stake in Apogee Therapeutics
Schedule 13G Filing
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Apogee Therapeutics Inc., totaling 2,518,725 common shares.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,518,725 shares of Apogee Therapeutics Inc. common stock.
- This ownership represents 5.5% of the total outstanding common shares of Apogee Therapeutics Inc.
- BlackRock holds sole voting power over 2,466,759 shares and sole dispositive power over 2,518,725 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- BlackRock, Inc. is a Delaware corporation with its principal business office at 50 Hudson Yards, New York, NY 10001.
- Apogee Therapeutics Inc.'s principal executive offices are located at 221 Crescent St., Building 17, Suite 102B, Waltham, MA 02453.
- Various BlackRock business units, including BlackRock Investment Management, LLC, contribute to the aggregate beneficial ownership, with BlackRock Investment Management, LLC beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. The presence of a large institutional investor like BlackRock can be seen as a neutral to slightly positive signal by some market participants.
Positives
- BlackRock, a major institutional investor, holding a 5.5% stake may signal confidence in Apogee Therapeutics Inc.'s long-term prospects.
- The filing indicates the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist intent to influence control.
Negatives
- The document does not contain information that would be considered negative regarding Apogee Therapeutics Inc.'s operations or financial performance.
Risks
- The document does not explicitly detail specific risks related to Apogee Therapeutics Inc.'s business or operations, as it is a passive ownership disclosure.
Future Outlook
The document, a Schedule 13G filing, does not provide any forward-looking statements or guidance regarding Apogee Therapeutics Inc.'s future performance or strategic outlook.
Industry Context
This filing reflects a significant passive investment by a major asset manager, BlackRock, in a biotechnology or pharmaceutical company, Apogee Therapeutics Inc. Such disclosures are common for large institutional investors accumulating stakes in publicly traded companies across various industries.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by BlackRock may influence investor perception and potentially share price, signaling institutional interest.
- Management: Awareness of a large, passive institutional holder may influence strategic considerations, though BlackRock's filing indicates no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was revoked. |
| 2025-01-21 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-07-16 | Signature date of the Schedule 13G filing by Spencer Fleming on behalf of BlackRock, Inc. |
Keywords
Apogee Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.